Top Markets
Coin of the day
Devonian Health Group Inc. Devonian Health Group Inc.

Devonian Health Group Inc.

DVHGF
Rang in aandelen #29820
Devonian Health Group Inc. specializes in the creation of botanical-based... Devonian Health Group Inc. specializes in the creation of botanical-based pharmaceutical drugs. Its leading product candidate, Thykamine, is currently undergoing Phase IIa clinical trials to treat conditions such as ulcerative colitis and atopic dermatitis. The company's development pipeline also includes Pantoprazole Magnesium for addressing gastric or duodenal ulcers, Cleo-35 targeting hormonal acne in women, and a range of value-added dermo-cosmetic products. Beyond its own development efforts, Devonian acquires licenses for and distributes various pharmaceutical and health products. Furthermore, the company has established a strategic partnership with CannTx Life Sciences Inc. to collaborate on the development of cannabinoid-based pharmaceutical drugs. Devonian Health Group Inc. was founded in 2015 and is based in Québec, Canada.
Aandeelprijs
$7.00
Laatst gesynchroniseerd: 2026-08-17
Marktkapitalisatie
$19.47M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
-35.19%
Land
CA
Handel Devonian Health Group Inc. (DVHGF)

Categorie

P/B-ratio voor Devonian Health Group Inc. (DVHGF)
P/B-ratio op 2026 TTM: 0
Volgens de meest recente financiële rapporten en aandelenkoers van Devonian Health Group Inc. is de huidige P/B-ratio (TTM) 0. Eind 2026 had het bedrijf een P/B-ratio van 0.
P/B-ratiohistoriek voor Devonian Health Group Inc. van 2026 tot 2026
P/B-ratio aan het einde van elk jaar
Jaar P/B-ratio Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
P/B-ratio voor vergelijkbare bedrijven of concurrenten
Bedrijf P/B-ratio Verschil in P/B-ratio Land
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR